Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-25T14:53:27.834Z Has data issue: false hasContentIssue false
  • English
  • Français

Value based pricing for NHS medicines: magic bullet, counterfeit treatment or the mixture as before?

Published online by Cambridge University Press:  01 October 2009

DAVID TAYLOR  and
TINA CRAIG
DAVID TAYLOR*
Affiliation:
Professor of Pharmaceutical and Public Health Policy, The School of Pharmacy, University of London, UK
TINA CRAIG
Affiliation:
Research Fellow, The School of Pharmacy, University of London, UK
*
*Corresponding author: David Taylor, Professor of Pharmaceutical and Public Health Policy, The School of Pharmacy, University of London, Mezzanine Floor, BMA/Tavistock House, London WC1H 9JP, UK. Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Perspective
Information
Health Economics, Policy and Law , Volume 4 , Issue 4 , October 2009 , pp. 515 - 526
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

BIS (2009), Pharmaceutical Price Regulation Scheme (PPRS). Final Government response to the recommendations aimed at Government contained in the OFT report ‘The Pharmaceutical Price Regulation Scheme’. London: The Department for Business, Innovation and Skills.Google Scholar
Claxton, K. (2007), ‘OFT, VBP: QED?’, Health Economics, 16: 545–558.CrossRefGoogle ScholarPubMed
Collier, J. (2008), ‘Changes to the regulation of drug prices in the UK’, British Medical Journal, 337: a2735.CrossRefGoogle Scholar
DoH (2008), The 2009 Pharmaceutical Price Regulation Scheme. See http://www.dh.gov.uk/en/Healthcare/Medicinespharmacyandindustry/Pharmaceuticalpriceregulationscheme/2009PPRS/DH_090499. Accessed 9 August 2009.Google Scholar
Jain, R.K. (2008), ‘Taming vessels to treat cancer’, Scientific American, 298: (1) 40–47.CrossRefGoogle ScholarPubMed
Mesure, S. (2007), ‘Energetic OFT head turns his guns on Big Pharma’, The Independent, 21 February 2007.Google Scholar
Office of Fair Trading (2007), The pharmaceutical price regulation scheme. An OFT market study. London: Office of Fair Trading.Google Scholar
Richards, M. (2008), Improving access to medicines for NHS patients: a report for the Secretary of State for Health by Professor Mike Richards. London: Department of Health.Google Scholar
Salter, B. (2004), The New Politics of Medicine. Basingstoke: Palgrave.CrossRefGoogle Scholar
Salter, B. (2008) Personal communication.Google Scholar
Taylor, D.G. and Maynard, A. (1990), Medicines, the NHS and Europe: balancing the public's interests. London: The Kings Fund Institute.Google Scholar
Thornton, S. (2007), ‘Drug price reform in the UK: debunking the myths’, Health Economics, 16: 981–992.CrossRefGoogle ScholarPubMed
Towse, A. (2007), ‘If it ain’t broke, don’t price fix it: the OFT and the PPRS’, Health Economics, 16: 653–665.CrossRefGoogle ScholarPubMed